ASCO GU 2023 Prostate Cancer - Results from #60

Viewing 61-80 of 95 articles

ASCO GU 2023: Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE): ECOG-ACRIN EA8191

ASCO GU 2023: Development and Validation of a Multi-Institutional Nomogram of Outcomes for PSMA-PET–based Salvage Radiotherapy in Recurrent Prostate Cancer

ASCO GU 2023: Real World Prospective Evaluation of Clinical Outcomes in Patients with Non-Metastatic Castrate Resistant Prostate Cancer Treated with Darolutamide

ASCO GU 2023: Baseline Characteristics Associated with PSA Progression-Free Survival in Patients (Pts) with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO Study (AFT-19)

ASCO GU 2023: Long-Term Safety and Tolerability of Darolutamide and Duration of Treatment in Patients with nmCRPC from the ARAMIS Rollover Study

ASCO GU 2023: Geographic Variation in Utilization of Doublet Therapy for Metastatic Prostate Cancer

ASCO GU 2023: Changes in Planned Disease Management after Piflufolastat F18 PET/CT in Men with Biochemically Recurrent Prostate Cancer and Low PSA Levels: A Secondary Analysis of Results from the CONDOR Study

ASCO GU 2023: Discussion of Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence Prognostic Biomarker and the FORMULA-509 Trial of Post-Operative Salvage Radiotherapy Post-Radical Prostatectomy

ASCO GU 2023: A Phase II Trial Modifying Metabolic Syndrome and Cardiovascular Risk for Patients with Prostate Cancer on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring (ProTrio)

ASCO GU 2023: EVOLUTION: Phase II Study of Radionuclide 177Lu-PSMA-617 Therapy Versus 177Lu-PSMA-617 in Combination with Ipilimumab and Nivolumab for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC; ANZUP 2001)

ASCO GU 2023: A Multi-Center, Prospective, Observational Study of Patients with Prostate Cancer Being Treated with Relugolix: OPTYX

ASCO GU 2023: A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR)

ASCO GU 2023: Increased Utilization of Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapy (PSMA-TRT) in African American (AA) Patients at an Academic Medical Center

ASCO GU 2023: 318: Positron emission tomography of patients with confirmed prostate cancer using 64Cu-SAR-bisPSMA

ASCO GU 2023: FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy

ASCO GU 2023: Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence Prognostic Biomarker in High-Risk Prostate Cancer: Results from Six NRG/RTOG Phase III Randomized Trials

ASCO GU 2023: Practice Patterns and Predictors of Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer

ASCO GU 2023: Machine-Learning to Predict Utility of Circulating Tumor DNA (ctDNA) for Somatic Genotyping

ASCO GU 2023: Cost-Effectiveness Analysis of Seven Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Public Payer Perspective Using Network Meta-Analysis

ASCO GU 2023: Circulating Tumor DNA Analysis of IMbassador250: Association of ctDNA Fraction, AR Alterations and Therapy Outcome in mCRPC

1
2
3
4
5